Top

Journal of Endocrinological Investigation

Published in:

01-12-2016 | Original Article

Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas

Authors: E. Sala, P. Bellaviti Buttoni, E. Malchiodi, E. Verrua, G. Carosi, E. Profka, G. Rodari, M. Filopanti, E. Ferrante, A. Spada, G. Mantovani

Published in: Journal of Endocrinological Investigation | Issue 12/2016

Abstract

Background

The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction.

Materials

We analyzed 74 patients (mean age = 46.9 ± 14.4, M/F = 19/55, macro/micro = 18/56) bearing a prolactinoma divided in 3 groups: group A (23) treated for 3 years, group B (23) for a period between 3 and 5 years, and group C (28) for a period >5 years. CAB therapy was interrupted according to Endocrine Society Guidelines. Prolactin (PRL) levels were measured 3, 6, 12 and 24 months after withdrawal. Recurrence was defined with PRL levels ≥30 ng/ml.

Results

Groups did not differ in pretreatment PRL levels (123.2 ± 112.1, 120.9 ± 123.8, 176.6 ± 154.0), pituitary deficit (4, 17, 17 %), mean CAB weekly dose (0.7 ± 0.4, 0.6 ± 0.3, 0.7 ± 0.4) and PRL levels before withdrawal (17.1 ± 19.6, 11.4 ± 8.8, 13.8 ± 13.5). Recurrence occurred within 12 months in 34 patients (45.9 %), without significant differences among groups. Neuroradiological evaluation showed a significantly higher presence of macroadenoma in group C (13, 17 and 39 %, respectively). Recurrence rate of hyperprolactinemia did not depend on sex, tumor size or CAB dose but it was significantly correlated with PRL levels at diagnosis and before withdrawal (p = 0.03). Finally, patients with pituitary deficit at diagnosis showed a significantly higher recurrence rate (p = 0.03).

Conclusions

The study provides additional evidence that prolonging therapy for more than 3 years does not reduce recurrence rate. In particular, recurrence risk was similar in micro- and macroadenomas, and higher in patients with pituitary deficits at diagnosis.

Faglia G (1991) Should dopamine agonist treatment for prolactinomas be lifelong. Clin Endocrinol Oxf 34:173–174CrossRefPubMed

Vitale G, Di Sarno A, Rota F, Lombardi G, Colao A (2003) When can we stop cabergoline treatment in prolactinomas? Curr Opin Endocrinol Diabetes 10:259–264CrossRef

Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43–51CrossRefPubMed

Ogilvie CM, Milsom SR (2011) Dopamine agonists in the treatment of prolactinoma: are they still first choice? Intern Med J 41:156–161CrossRefPubMed

Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67–99CrossRefPubMed

Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68:104–112PubMed

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed

Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol Oxf 63:26–31CrossRefPubMed

10.

Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G (2007) Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol Oxf 67:426–433CrossRefPubMed

11.

Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428–2436CrossRefPubMedPubMedCentral

12.

Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA (2011) Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol Oxf 75:819–824CrossRefPubMed

13.

Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M (2012) Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15:25–29CrossRefPubMed

14.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoural and nontumoural hyperprolactinemia. N Engl J Med 349:2023–2033CrossRefPubMed

15.

Mehmet S, Powrie JK (2003) A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clin Endocrinol Oxf 58:111–113CrossRefPubMed

16.

Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci 22:1562–1567CrossRefPubMed

17.

Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62:1864–1869CrossRefPubMed

18.

Vallette S, Serri K, Serri O (2010) Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther 8:49–54CrossRefPubMed

19.

Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153–157CrossRefPubMed

20.

Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261CrossRefPubMed

21.

Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN (2009) Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol 161:819–828CrossRefPubMed

22.

Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72:507–511CrossRef

Title: Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas
Authors: E. Sala
P. Bellaviti Buttoni
E. Malchiodi
E. Verrua
G. Carosi
E. Profka
G. Rodari
M. Filopanti
E. Ferrante
A. Spada
G. Mantovani
Publication date: 01-12-2016
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 12/2016
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-016-0483-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2016

The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study

Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association

Insulin, insulin receptors, and cancer

Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes

Relationship of galectin-3 with obesity, IL-6, and CRP in women

Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials